Innovative Pyrazole–Thiazole–Oxadiazole Hybrid Compounds for Targeted EGFR/VEGFR2 Inhibition in Cancer Treatment
Archiv der Pharmazie · 2025-10 · 358 (10)
DOI: 10.1002/ardp.70122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 13.10.2025. Verfasst von Burak Kuzu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Van Yuzuncu Yil University, Van, Türkiye. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Pyrazoles, Antineoplastic Agents, Oxadiazoles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
A new series of pyrazole–thiazole–oxadiazole hybrid compounds targeting the EGFR and VEGFR2 enzymes was designed and synthesized using innovative approaches. The compounds were characterized through spectral methods, and their cytotoxic activities were evaluated against the A549 lung and HT‐29 colon cancer cell line using the MTT assay. Among them, compounds 17i and 17m exhibited notable cytotoxicity, with 17i demonstrating approximately threefold greater activity compared to the reference drug sorafenib for A549 cells. Flow cytometry analysis revealed that 17i induced extensive necrotic cell death, while 17m triggered a more targeted and controlled apoptotic mechanism. In vitro enzyme inhibition assays demonstrated that 17i inhibited EGFR and VEGFR2 with IC 50 values of 0.158 and 0.128 µM, respectively. In contrast, 17m exhibited more potent inhibition of EGFR (IC 50 = 0.012 µM) and moderate activity against VEGFR2 (IC 50 = 0.309 µM). Molecular docking and molecular dynamics simulations further supported the structural stability of the complexes formed by these compounds with their target enzymes, highlighting their potential as effective enzyme inhibitors. Collectively, these findings suggest that pyrazole–thiazole–oxadiazole hybrids represent promising candidates for targeted cancer therapy at the cellular level.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Van Yuzuncu Yil University, Van, Türkiye.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir, Türkiye.
- Central Analysis Laboratory, Faculty of Pharmacy, Anadolu University, Eskişehir, Türkiye.
- Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Anadolu University, Eskişehir, Türkiye.
ORCID-Profile: Burak Kuzu, Derya Osmaniye, Yusuf Özkay
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Kuzu, B., Osmaniye, D., Karaduman, A. B., & Özkay, Y. (2025). Innovative Pyrazole–Thiazole–Oxadiazole Hybrid Compounds for Targeted EGFR/VEGFR2 Inhibition in Cancer Treatment. Archiv der Pharmazie, 358(10). https://doi.org/10.1002/ardp.70122
Vancouver
Kuzu B, Osmaniye D, Karaduman AB, Özkay Y. Innovative Pyrazole–Thiazole–Oxadiazole Hybrid Compounds for Targeted EGFR/VEGFR2 Inhibition in Cancer Treatment. Archiv der Pharmazie. 2025;358(10). doi:10.1002/ardp.70122
BibTeX
@article{Kuzu2025,
author = {Kuzu, Burak and Osmaniye, Derya and Karaduman, Abdullah Burak and Özkay, Yusuf},
title = {Innovative Pyrazole–Thiazole–Oxadiazole Hybrid Compounds for Targeted EGFR/VEGFR2 Inhibition in Cancer Treatment},
journal = {Archiv der Pharmazie},
year = {2025},
volume = {358},
number = {10},
doi = {10.1002/ardp.70122}
}
EUVIMED